Spruce Biosciences (SPRB) Competitors $0.40 +0.02 (+4.68%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SPRB vs. ONCY, BYSI, VNRX, ATRA, SPRO, CNTB, MURA, IVVD, AADI, and KRONShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Oncolytics Biotech (ONCY), BeyondSpring (BYSI), VolitionRx (VNRX), Atara Biotherapeutics (ATRA), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Mural Oncology (MURA), Invivyd (IVVD), Aadi Bioscience (AADI), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Oncolytics Biotech BeyondSpring VolitionRx Atara Biotherapeutics Spero Therapeutics Connect Biopharma Mural Oncology Invivyd Aadi Bioscience Kronos Bio Oncolytics Biotech (NASDAQ:ONCY) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do analysts prefer ONCY or SPRB? Oncolytics Biotech currently has a consensus target price of $4.00, indicating a potential upside of 381.35%. Spruce Biosciences has a consensus target price of $3.90, indicating a potential upside of 875.00%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Oncolytics Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Spruce Biosciences 0 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ONCY or SPRB more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.15% -84.73% Spruce Biosciences -555.23%-62.10%-47.49% Does the MarketBeat Community favor ONCY or SPRB? Oncolytics Biotech received 117 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 68.12% of users gave Oncolytics Biotech an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformOncolytics BiotechOutperform Votes15668.12% Underperform Votes7331.88% Spruce BiosciencesOutperform Votes3954.93% Underperform Votes3245.07% Does the media favor ONCY or SPRB? In the previous week, Spruce Biosciences had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Spruce Biosciences and 2 mentions for Oncolytics Biotech. Spruce Biosciences' average media sentiment score of 0.42 beat Oncolytics Biotech's score of -0.24 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, ONCY or SPRB? Oncolytics Biotech has higher earnings, but lower revenue than Spruce Biosciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$20.56M-$0.27-3.08Spruce Biosciences$7.10M2.33-$47.92M-$0.94-0.43 Do insiders and institutionals hold more shares of ONCY or SPRB? 6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ONCY or SPRB? Oncolytics Biotech has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. SummarySpruce Biosciences beats Oncolytics Biotech on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.52M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.4310.5991.3417.19Price / Sales2.33195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.215.104.794.78Net Income-$47.92M$151.51M$120.07M$225.60M7 Day Performance4.38%-2.15%-1.89%-1.24%1 Month Performance-18.53%-3.14%11.45%3.36%1 Year Performance-80.49%11.50%30.61%16.58% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences3.8205 of 5 stars$0.40+4.7%$3.90+875.0%-75.6%$16.52M$7.10M-0.4320Analyst RevisionONCYOncolytics Biotech1.9095 of 5 stars$0.81-0.4%$4.00+393.8%-33.0%$62.43MN/A-3.0030News CoverageBYSIBeyondSpringN/A$1.60-2.7%N/A+72.8%$62.25M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx1.7538 of 5 stars$0.67+18.6%$3.75+459.7%+2.4%$62.09M$770,000.00-1.5780Gap UpATRAAtara Biotherapeutics3.8375 of 5 stars$10.59+2.5%$16.67+57.4%-17.6%$61.00M$100.44M-0.40165Analyst ForecastNews CoverageGap UpSPROSpero Therapeutics4.5453 of 5 stars$1.10+2.3%$5.00+356.6%-29.3%$59.70M$103.78M15.2946Analyst DowngradeNews CoverageCNTBConnect Biopharma3.4741 of 5 stars$1.08-3.4%$8.00+640.7%+11.9%$59.68M$24.12M0.00110Positive NewsGap DownMURAMural Oncology3.0898 of 5 stars$3.45-5.2%$16.00+363.8%-9.1%$58.72MN/A-0.40119Negative NewsGap UpIVVDInvivyd3.781 of 5 stars$0.49-10.7%$7.89+1,515.0%-87.0%$58.42M$11.56M-0.28100News CoverageGap DownAADIAadi Bioscience1.6327 of 5 stars$2.37-1.7%$1.67-29.7%+64.6%$58.41M$25.07M-1.0640News CoverageGap UpKRONKronos Bio3.352 of 5 stars$0.95-2.6%$1.63+70.3%-14.5%$57.59M$9.86M-0.69100 Related Companies and Tools Related Companies Oncolytics Biotech Competitors BeyondSpring Competitors VolitionRx Competitors Atara Biotherapeutics Competitors Spero Therapeutics Competitors Connect Biopharma Competitors Mural Oncology Competitors Invivyd Competitors Aadi Bioscience Competitors Kronos Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts